Money, Pharmaceuticals and health products
Teva Pharmaceuticals USA Inc. Political Action Committee (TEVA PAC)
Corporation connected to Teva Pharmaceuticals USA, Inc., Washington, DC. FEC committee C00434811.
Teva Pharmaceuticals USA Inc. Political Action Committee (TEVA PAC) is the political action committee of Teva Pharmaceuticals USA, Inc., a company in the pharmaceuticals and health products field. It collects voluntary contributions from the organization's employees or members and gives them to candidates. Since 2021 it has given $129K to members of Congress. 79% of its money in 2025-26 helped Democrats.
Who its money helped, 2025-26
79% Democrats $23K21% Republicans $6K
- Given to members
- $23K
- 9 recipients in 2022
- To Democrats
- 26%
- $6K
- To Republicans
- 74%
- $17K
- Lobbying, 2025-26
- $4.31M
- Lobbying Disclosure Act filings
Recipients
Share is the gift's part of everything that member raised in the 2021-22 cycle. Open a row for every contribution.
| Member | Given | Share | 2022 race |
|---|---|---|---|
Sen. John ThuneR South Dakota2 contributions, 20222021-22: $5,400
| $5,400 | <0.1% | Won |
Sen. John R. CurtisR Utah11 contributions, 2021 to 20232021-22: $10,0002023-24: $10,000
| $4,500 | 0.21% | Won |
Sen. Ron WydenD Oregon5 contributions, 2021 to 20222021-22: $6,500
| $4,000 | <0.1% | Won |
Sen. Bill CassidyR Louisiana4 contributions, 2022 to 20262021-22: $2,5002023-24: $7,5002025-26: -$5,000
| $2,500 | <0.1% | |
Rep. Gus M. BilirakisR Florida 12th3 contributions, 20222021-22: $2,500
| $2,500 | 0.13% | Won |
Rep. Richard HudsonR North Carolina 9th1 contribution, 20222021-22: $1,000
| $1,000 | <0.1% | Won |
Rep. Donald S. Beyer, Jr.D Virginia 8th1 contribution, 20222021-22: $1,000
| $1,000 | <0.1% | Won |
Rep. Andy HarrisR Maryland 1st1 contribution, 20222021-22: $1,000
| $1,000 | <0.1% | Won |
Sen. Patty MurrayD Washington1 contribution, 20222021-22: $1,000
| $1,000 | <0.1% | Won |
What Teva Pharmaceuticals USA, Inc. lobbies on
Bills named in filings: H.R. 1843, H.R. 6888, S. 959, S.J.Res. 37.








